# Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study

> **NCT00630786** · PHASE1,PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 53 (actual)

## Conditions studied

- Colon Cancer
- Colorectal Cancer
- Rectal Cancer
- Metastatic Colorectal Cancer
- Oncology

## Interventions

- **DRUG:** Panitumumab
- **DRUG:** Conatumumab

## Key facts

- **NCT ID:** NCT00630786
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-05
- **Final completion:** 2010-11
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2014-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00630786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00630786, "Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00630786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*